RVL ($NASDAQ:RVLP) Pharmaceuticals reported their financial results for the second quarter of the fiscal year 2023, ending on June 30th 2023. Revenue for the quarter was 8.3 million USD, a slight decrease of 2.2% from the same quarter in the previous year. Net income for the quarter was -23.9 million USD, a substantial improvement from the loss of -12.1 million USD in the same quarter of the previous year.
RVL PHARMACEUTICALS reported impressive second quarter results for FY2023 on Monday. The stock opened at $0.5 and closed at $0.4, a 14.9% plunge from the prior closing price of 0.5. Investors were surprised by the dismal performance of the company, as it had been expected to report positive returns. This strong performance was attributed to the company’s expansion into new markets as well as its focus on developing new products.
Despite the impressive performance for the quarter, RVL PHARMACEUTICALS stock was still unable to recover from its losses. This is likely due to investor’s concerns that the company may face difficulties in the near future if it is not able to sustain its growth or if there are further developments in the competitive landscape. With the uncertainties surrounding the sector, investors are advised to exercise caution when investing in RVL PHARMACEUTICALS stock. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Rvl Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Rvl Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Rvl Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Rvl Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
This kind of company might interest value investors, who prioritize capital preservation and place emphasis on a company’s fundamentals. RVL PHARMACEUTICALS has an intermediate health score of 4/10, which suggests that it might be able to sustain future operations in times of crisis. Furthermore, it is strong in medium profitability and weak in asset, dividend, and growth. Therefore, RVL PHARMACEUTICALS may be an interesting investment opportunity for value investors as long as they understand the risks associated with the company’s financial health. More…
Risk Rating Analysis
Star Chart Analysis
The company has a number of competitors, including Biomed-Lublin Wytwornia Surowic i Szczepionek SA, Verde Science Inc, and Ocumension Therapeutics.
– Biomed-Lublin Wytwornia Surowic i Szczepionek SA ($LTS:0RKM)
Biomed-Lublin Wytwornia Surowic i Szczepionek SA is a Polish company that manufactures and supplies vaccines and immunoglobulins. The company has a market cap of 463.48M as of 2022 and a Return on Equity of 6.21%. Biomed-Lublin Wytwornia Surowic i Szczepionek SA is a leading provider of vaccines and immunoglobulins in Poland. The company offers a wide range of vaccines and immunoglobulins for the prevention and treatment of infectious diseases.
Verde Science Inc is a technology company that focuses on the development and commercialization of medical cannabis products. The company has a market cap of 45.35k as of 2022 and a ROE of 26.96%. Verde Science Inc’s products are designed to improve the quality of life for patients suffering from various conditions, including pain, anxiety, and sleep disorders. The company’s products are available in a variety of formulations, including tinctures, capsules, and topicals.
– Ocumension Therapeutics ($SEHK:01477)
Ocumension Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of therapeutic solutions for vitreoretinal diseases. The company’s lead product candidate, OTX-TP, is a novel intravitreal drug delivery system that is being developed for the treatment of retinal diseases. The company has a market cap of 6.07B as of 2022 and a Return on Equity of -7.87%.
RVL Pharmaceuticals recently reported their financial results for Q2 FY2023, with total revenue of 8.3 million USD, representing a 2.2% decrease year-over-year. Net income for the quarter was -23.9 million USD, an increase from the prior year. This news sent the stock price down the same day. Investors should exercise caution when considering RVL Pharmaceuticals as a potential investment option, given the current financial performance of the company.
The lack of revenue growth combined with negative net income is a strong warning sign. It is advised to monitor their future reports carefully and watch for signs of a possible turnaround before considering investing in this stock.